JP2018511327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511327A5 JP2018511327A5 JP2017551176A JP2017551176A JP2018511327A5 JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5 JP 2017551176 A JP2017551176 A JP 2017551176A JP 2017551176 A JP2017551176 A JP 2017551176A JP 2018511327 A5 JP2018511327 A5 JP 2018511327A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- ankyrin repeat
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 102000008102 Ankyrins Human genes 0.000 claims 19
- 108010049777 Ankyrins Proteins 0.000 claims 19
- 102000023732 binding proteins Human genes 0.000 claims 18
- 108091008324 binding proteins Proteins 0.000 claims 18
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000057308 human HGF Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| EP15162511.8 | 2015-04-02 | ||
| EP15162502.7 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511327A JP2018511327A (ja) | 2018-04-26 |
| JP2018511327A5 true JP2018511327A5 (cg-RX-API-DMAC7.html) | 2018-11-22 |
| JP6552636B2 JP6552636B2 (ja) | 2019-07-31 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551176A Active JP6552636B2 (ja) | 2015-04-02 | 2016-04-01 | 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン |
Country Status (20)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| DK2643349T3 (da) * | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| MX377424B (es) * | 2016-09-22 | 2025-03-10 | Molecular Partners Ag | Proteinas de union recombinantes y sus usos |
| CN110959015B (zh) * | 2017-07-12 | 2023-07-25 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| SG11202001420VA (en) * | 2017-08-18 | 2020-03-30 | Cambridge Entpr Ltd | Modular binding proteins |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| EP3941580A1 (en) * | 2019-03-22 | 2022-01-26 | Reflexion Pharmaceuticals, Inc. | D-peptidic compounds for vegf |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| EP3980443A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Multispecific proteins |
| CN114206908B (zh) * | 2019-06-04 | 2025-12-23 | 分子伴侣公司 | 具有改善的稳定性的经设计的锚蛋白重复结构域 |
| CA3139164A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| WO2021116462A1 (en) * | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| JP2023506763A (ja) | 2019-12-11 | 2023-02-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えペプチド－ｍｈｃ複合体結合タンパク質並びにそれらの生成及び使用 |
| TW202208404A (zh) * | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| US20240279309A1 (en) * | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| CN115768786A (zh) | 2020-05-14 | 2023-03-07 | 分子合作伙伴股份公司 | 多特异性蛋白质 |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| CA3202358A1 (en) * | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| EP4263608A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Partners AG | Recombinant cd3 binding proteins and their use |
| JP2024509904A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| AU2022413461A1 (en) | 2021-12-14 | 2024-06-06 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| CN119731200A (zh) | 2022-08-01 | 2025-03-28 | 分子合作伙伴股份公司 | 经电荷修饰设计的重复结构域及其用途 |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| US20250332297A1 (en) | 2024-01-31 | 2025-10-30 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2005303912B2 (en) | 2004-11-12 | 2011-02-17 | Bayer Schering Pharma Aktiengesellschaft | Recombinant Newcastle Disease Virus |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| WO2007006665A1 (en) | 2005-07-08 | 2007-01-18 | University Of Zürich | Phage display using cotranslational translocation of fusion polypeptides |
| AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
| EA021222B8 (ru) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro |
| WO2009040338A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zürich | Designed armadillo repeat proteins |
| WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| CN110437320B (zh) * | 2010-07-09 | 2023-10-20 | 阿菲博迪公司 | 多肽 |
| AU2011281702A1 (en) * | 2010-07-19 | 2013-01-31 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| EP2643351A1 (en) * | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| DK2643349T3 (da) | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en not_active Ceased
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 MX MX2017012485A patent/MX393655B/es unknown
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Ceased
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt not_active Application Discontinuation
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en not_active IP Right Cessation
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active Active
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en not_active Ceased
- 2016-04-01 PH PH1/2017/501792A patent/PH12017501792B1/en unknown
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active